HC Wainwright Reaffirms Neutral Rating for Lumos Pharma (NASDAQ:LUMO)

HC Wainwright reissued their neutral rating on shares of Lumos Pharma (NASDAQ:LUMO) in a research report released on Thursday morning, Marketbeat Ratings reports. The brokerage currently has a $4.25 price target on the stock, down from their prior price target of $28.00.

Several other brokerages have also commented on LUMO. Oppenheimer dropped their price target on shares of Lumos Pharma from $16.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. EF Hutton Acquisition Co. I raised shares of Lumos Pharma to a “strong-buy” rating in a research report on Tuesday, September 24th.

Lumos Pharma Price Performance

Shares of Lumos Pharma stock traded up $0.01 during trading on Thursday, hitting $4.36. 2,444 shares of the stock were exchanged, compared to its average volume of 48,087. The stock has a market cap of $35.40 million, a price-to-earnings ratio of -0.98 and a beta of 0.78. The firm’s 50-day moving average price is $3.77 and its 200 day moving average price is $2.82. Lumos Pharma has a 12-month low of $1.37 and a 12-month high of $4.58.

Lumos Pharma (NASDAQ:LUMO) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.33. Lumos Pharma had a negative return on equity of 157.99% and a negative net margin of 2,405.72%. The company had revenue of $0.49 million during the quarter. During the same period last year, the firm earned ($1.09) earnings per share. As a group, research analysts forecast that Lumos Pharma will post -2.96 earnings per share for the current year.

Institutional Trading of Lumos Pharma

An institutional investor recently raised its position in Lumos Pharma stock. Private Advisor Group LLC raised its position in Lumos Pharma, Inc. (NASDAQ:LUMO) by 2,380.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 744,513 shares of the company’s stock after buying an additional 714,500 shares during the quarter. Private Advisor Group LLC owned approximately 9.17% of Lumos Pharma worth $2,881,000 as of its most recent filing with the Securities and Exchange Commission. 33.99% of the stock is currently owned by hedge funds and other institutional investors.

About Lumos Pharma

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.